Experienced in X-Linked Dystonia-Parkinsonism

Dr. Basil T. Darras

Pediatric Neurology | Pediatrics | Medical Genetics
C H Neurology Foundation Inc
300 Longwood Ave, 
Boston, MA 
 (80.0 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in X-Linked Dystonia-Parkinsonism
C H Neurology Foundation Inc
300 Longwood Ave, 
Boston, MA 
 (80.0 mi)
OverviewInsuranceLocationsClinical Research

Overview

Basil Darras is a Pediatric Neurologist and a Pediatrics provider in Boston, Massachusetts. Dr. Darras and is rated as an Experienced provider by MediFind in the treatment of X-Linked Dystonia-Parkinsonism. His top areas of expertise are Spinal Muscular Atrophy (SMA), Primary Lateral Sclerosis, Spinal Muscular Atrophy Type 2, and Spinal Muscular Atrophy Type 3. Dr. Darras is currently accepting new patients.

His clinical research consists of co-authoring 195 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Neurology
Pediatrics
Medical Genetics
Licenses
Neurology with Special Qualifications in Neurology in MA
Hospital Affiliations
Boston Children's Hospital
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

C H NEUROLOGY FOUNDATION INC
300 Longwood Ave, Boston, MA 02115

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
A Prospective, Long-Term Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Enrollment Status: Recruiting
Publish Date: January 31, 2025
Intervention Type: Drug, Other
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
Enrollment Status: Recruiting
Publish Date: October 12, 2023
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug
Study Drug: Nusinersen
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Biological
Study Phase: Phase 3
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Who Completed the SIDEROS Study
Enrollment Status: Terminated
Publish Date: December 03, 2021
Intervention Type: Drug
Study Drug: Idebenone
Study Phase: Phase 3
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy
Enrollment Status: Completed
Publish Date: August 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Phaseout DMD: A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With Ezutromid in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy (SMT C11005)
Enrollment Status: Terminated
Publish Date: January 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)
Enrollment Status: Completed
Publish Date: June 07, 2018
View 13 Less Clinical Trials

194 Total Publications

Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.
Long-term natural history in type II and III spinal muscular atrophy: a 4-year international study on the Hammersmith Functional Motor Scale Expanded.
Journal: European journal of neurology
Published: July 17, 2024
Similar Doctors
Elite in X-Linked Dystonia-Parkinsonism
Dr. Nutan Sharma
Neurology
Elite in X-Linked Dystonia-Parkinsonism
Dr. Nutan Sharma
Neurology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.6 mi)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nutan Sharma is a Neurologist in Boston, Massachusetts. Dr. Sharma and is rated as an Elite provider by MediFind in the treatment of X-Linked Dystonia-Parkinsonism. Her top areas of expertise are Drug Induced Dyskinesia, Focal Dystonia, X-Linked Dystonia-Parkinsonism, Dopa-Responsive Dystonia, and Deep Brain Stimulation. Dr. Sharma is currently accepting new patients.

Advanced in X-Linked Dystonia-Parkinsonism
Dr. Michael T. Hayes
Neurology
Advanced in X-Linked Dystonia-Parkinsonism
Dr. Michael T. Hayes
Neurology

Brigham And Womens Physicians Organization Inc

75 Francis St, 
Boston, MA 
 (0.1 mi)
617-732-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Hayes is a Neurologist in Boston, Massachusetts. Dr. Hayes and is rated as a Distinguished provider by MediFind in the treatment of X-Linked Dystonia-Parkinsonism. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Familial Paroxysmal Nonkinesigenic Dyskinesia, Dopa-Responsive Dystonia, and Gastrostomy. Dr. Hayes is currently accepting new patients.

Advanced in X-Linked Dystonia-Parkinsonism
Dr. David K. Simon
Neurology
Advanced in X-Linked Dystonia-Parkinsonism
Dr. David K. Simon
Neurology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (0.2 mi)
617-754-8612
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

David Simon is a Neurologist in Boston, Massachusetts. Dr. Simon and is rated as a Distinguished provider by MediFind in the treatment of X-Linked Dystonia-Parkinsonism. His top areas of expertise are Parkinson's Disease, Serotonin Syndrome, X-Linked Dystonia-Parkinsonism, MELAS Syndrome, and Deep Brain Stimulation. Dr. Simon is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile